Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

FDA approval of LYTENAVA TM (ophthalmic bevacizumab) creates a first FDA-approved product in the U.S. for wet AMD, addressing an unmet need despite bevacizumab’s widespread off-label use. The news is supportive for regulatory credibility and potential market uptake in a large treated segment.

Analysis

FDA approval of LYTENAVA TM (ophthalmic bevacizumab) creates a first FDA-approved product in the U.S. for wet AMD, addressing an unmet need despite bevacizumab’s widespread off-label use. The news is supportive for regulatory credibility and potential market uptake in a large treated segment.